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1. Introduction 
Cancer is the second leading cause of death in the Western world.  Whilst there are many 
therapies which can significantly improve patient outcomes, there is still no definitive
“cure” for cancer. Over the last decade we have witnessed gene therapy developing at a
very fast pace representing a potential new and more effective modality for the treatment of
cancer. By the end of 2010, over 1060 gene therapy protocols have been proposed or trialled
in the clinical setting for various cancers; this figure represents over 64% of all gene therapy 
trials in humans in the United States.  From many of these trials modest therapeutic
responses have been reported, however, unequivocal proof of clinical efficacy is still to be 
seen. In 2003, the first commercially produced gene based product was manufactured by 
Shenzhen SiBiono GeneTech. Gendicine™, a replication-incompetent recombinant human 
Ad5-p53, was approved by the Chinese State Food and Drug Administration to treat head 
and neck squamous cell carcinoma.  Again in 2006, Shanghai Sunway Biotech, commercially 
released a conditionally replicative adenovirus therapy, Oncorine™[8].  However, it is fair 
to say that cancer gene therapy has yet to realise its full potential.
2. The gene therapy vector systems 
An important feature for any successful gene therapy protocol is the vector system. To date, 
a number of vectors have been developed, including both viral and non-viral based therapy 
systems (Table 1). Each of these vectors possesses a number of unique features and each has
its own advantages and disadvantages.  The most promising existing vectors are the 
replication-competent oncolytic viral vector based gene therapy systems, particularly the 
adenoviruses[9, 10]. 
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300 Gene Therapy - Developments and Future Perspectives 
Vector Advantages Disadvantages 
Adenovirus
Easy to produce, Can achieve 
high titre, High efficiency of gene 
transfer 
Large DNA virus, many viral
genes, often Immunogenic
Adeno-associated 
virus 
Retrovirus 
Herpesvirus 
Viral replicons:
Semliki Forest virus 
Non-viral vectors 
Relatively easy to produce, Has 
ability for gene integration 
Can be made through packaging 
cells, Has ability for gene 
integration 
Has Neurotropic affinity, Can be 
applied to Neurons or Glioma
Easy production, less
immunogenic
Simple, easy to make and easy to 
use 
Wide type Adenovirus 
contamination 
Low efficiency of gene  
transfer, dividing cells only
Large DNA virus, many viral
genes, Immunogenic
Difficult to purify 
Low efficiency 
Table 1. List of commonly used vectors for cancer gene therapy as well as their advantages 
and disadvantages 
3. Viral vector systems  
3.1 Adenoviral vectors
Adenovirus vector (AV) is the most commonly studied and most widely used system in
cancer gene therapy. It is of particular use for cancer gene therapy applications, where 
temporary gene expression is acceptable or even beneficial. There are several serotypes, but 
the currently employed AVs in clinical trials are mostly based on serotype 5. These vectors
can replicate highly and have demonstrated efficient gene transfer into various types of
cancer cells[11]. Two AVs related gene therapy products have been approved for clinical use 
in patients suffering from head and neck cancers in China, replication-incompetent 
recombinant human Ad5-p53[12], and the other is a conditionally replicative adenovirus
therapy. 
Several other adenoviruses, based on canine, porcine, bovine, ovine and avian adenoviruses
have been developed. The ovine AV is based on serotype 7 and was developed in Australia. 
Preclinical testing of ovine AV on prostate cancer in animal models has shown therapeutic 
efficacy[13].  
Unfortunately, AVs contain many viral genes which encode for major proteins that elicit a 
strong host immune response. Of particular concern is the release of cytotoxic T 
lymphocytes that lyse cells expressing the recombinant genes. Newer generations of AV 
vector have been designed to overcome some of these problems and initial results are
encouraging. New techniques involved in removing the recombinant viral genes and 
transfecting the non-recombinant plasmid with a helper virus and then separating the
helper virus with sedimentation techniques have been developed. Improvements in helper 
virus have also been trialled that reduces "floxed" helper virus production 1000-fold, but this 
method still has a 1% wide type (WT) contamination thus still allowing the possibility of in 
vivo recombination. With regard to AV-mediated cancer treatment, high-level tumour 
transduction remains a key developmental hurdle. To this end, AV vectors possessing 
infectivity enhancement and targeting capabilities should be evaluated in the most stringent 
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301Cancer Gene Therapy - Developments and Future Perspectives 
model systems possible. Advanced AV-based vectors with imaging, targeting and
therapeutic capabilities have yet to be fully realized; however, the feasibilities leading to this
accomplishment are within close reach[14]. 
3.2 Adeno-associated virus (AAV)-based vectors
AAV-based vectors have been shown to be non-toxic and undergo widespread cellular 
uptake in preclinical evaluation[15]. A recent study has compared five different AAV strains
and amongst them, serotype 2 was proven to be the most efficient killers of tumour cells. In 
another study, serotype 8 AAV vector encoding a soluble vascular endothelial growth factor 
(VEGF) receptor was able to halt tumour growth in several rodent glioma models. However, 
difficulties in the development of packaging cell lines for AAV, as well as bulk production 
and vector purification have been reported as problematic[16]. A new system was 
developed recently to scale up and bulk production of AAV from insect cells which may 
solve some of these existing problems[16]. 
3.3 Retroviral vectors  
The earliest system that was developed for gene therapy was the murine Moloney
leukaemia virus (MoMLV)-based retroviral vector.  More than 23% of all gene therapy trials
in patients for various diseases have used a replication-defective or competent MoMLV 
vector system.  This vector’s unique ability to transduce dividing cells[17] makes it an ideal 
choice of vector for continuously dividing and fast growing tumours, such as gliomas.
However, poor vector penetration and lack of vector migration away from the injection site 
is usually seen[18]. To overcome this effect, replication competent MoMLV was developed. 
A 2005 publication showed complete transduction of human U87 glioma xenografts in nude
mice after a single intracranial (i.c.) injection of replication-competent MoMLV[19]. In this
study, viral envelope was stained positively in glioma cells away from the injection sites.
Most importantly, no virus was detected in any non-tumour tissue which is good indication
of strict tumour specificity.
Potential limitations of retroviral vector systems are related to their ability to activate
cellular oncogenes and inactivate tumour suppressor genes by insertional mutagenesis. One 
study used MoMLV to transduce bone marrow stem cells for the therapy of severe
combined immune deficiency syndrome (SCID), following treatment 4 out of 11 children 
subsequently developed leukaemia[20]. In addition to improving safety, there are also
studies that have shown that dissemination of the vectors in solid tumours still needed to be 
improved in order to reach clinical efficacy. 
Lentiviral vectors are a more recently developed and complicated retroviral vector, based on 
the Human or Bovine Immunodeficiency Virus. They have all the unique features of 
MoMLV and have been shown to transduce post mitotic cells in vitro and in vivo[21]. Studies 
with the Human Immunodeficiency Virus (HIV)-based vectors have shown efficient gene 
transfer in tumour models. An understandable reluctance in the use of potentially 
pathogenic HIV vectors in humans has been seen, although a clinical trial assessing use of 
lentiviral vector for the therapy of AIDS is underway[22]. To reduce the risk of 
seroconversion in human patients several bovine based vector systems have been 
developed, which have the advantage of less or no pathogenicity in humans. We have also 
developed a bovine lentiviral vector system based on the Jembrana Disease virus (JDV)[23,
24]. JDV only causes disease in a specific species of cattle in the Jembrana district in Bali, 
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302 Gene Therapy - Developments and Future Perspectives 
Indonesia, but does not affect humans. Pathological changes in cattle include intense non­
follicular lympho-proliferation by reticulum and lymphoblastoid cells in lymphoid organs.
Protein and genome sequence studies have confirmed that JDV has a genome of 7732
nucleotides and structure and organisation similar to other members of the lentivirus
family. More importantly, JDV possesses several features in common with HIV that are very 
attractive as a vector, including a high replication rate and the ability to efficiently integrate
into chromosomes of non-dividing and terminally differentiated cells.
3.4 Herpesvirus-based vectors 
Vectors based on herpesviruses are well-developed and have progressed to clinical trials. As 
with other viral vectors, replication-defective vectors have not shown much potential. The 
first replication competent vector was based on a mutant strain, where the vectors are 
deleted from the main neurovirulence gene r34.5, thus restricting its ability to replicate in 
adult central nervous system and to form latency. However, later study showed that the 
mutant strain which had the deletion of the r34.5 gene also had reduced capacity for 
replication inside tumour cells[25]. New vectors were developed with a deletion of the
ICP47 gene which does not appear to impact on efficient replication. 
Pre-existing immunity may pose a problem that limits the clinical efficacy of herpesvirus-
based vectors. This immunity prevents the transduction of peripheral organs and also can 
cause liver toxicity. However, a recent mutant strain-secreting cytokine granule macrophage
colony stimulatory factor (GM-CSF) or IL-12 was shown to be effective in liver cancer 
therapy in a murine model which likely involves both direct viral oncolysis and actions of 
specific immune effector cells[26]. 
3.5 Viral replicons and transposons
Semliki Forest virus (SFV) subgenomic replicons (i.e. non toxic replication) have been 
developed that allow stable expression of a required gene e.g. beta-galactosidase (beta-Gal) 
in mammalian cell lines. Studies showed that expression remained high (approximately 150 
pg per cell) throughout cell passages[27]. 
Since construction of the Sleeping Beauty transposon from defective copies of a Tc1/mariner 
fish element[28], new vertebrate genetic manipulation tools (i.e. transposase enzymes) have 
become available for gene therapy. This particular transposase in the system binds to the
inverted repeats of salmonid transposons that surround the insertion gene and mediate 
precise 'cut and paste' into fish, mouse and human chromosomes. Potential problems with 
the use of transposons for gene therapy may arise from having no 'off' switch for the
transposase and the relatively low quantities of integrated product, either of which would 
make retroviral intergrase a more suitable or alternative enzyme for chromosomal
integration.  
3.6 Targeted viral vectors
While efforts have been focused on the continuing refinement of various vector systems, 
several obstacles remain, primarily the low efficiency of gene delivery into target tumour 
cells. The vascular endothelial wall is a significant physical barrier prohibiting access of 
systemically administered vectors to the tumour cell. To overcome this obstacle, strategies
are currently being developed to take advantage of transcytosis pathways through the
endothelium. An AV vector targeted to the transcytosing transferrin receptor pathway,
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303Cancer Gene Therapy - Developments and Future Perspectives 
using the bifunctional adapter molecule has been constructed[29]. The transcytosed AV 
virions retain the ability to infect cells, establishing the feasibility of this approach. However, 
efficiency of AV trafficking via this pathway is poor. Other efforts are directed towards 
exploring other transcytosing pathways such as the melanotransferrin pathway, the poly-
IgA receptor pathway, or caveolae-mediated transcytosis pathways. There are hopes to 
develop mosaic AV vectors incorporating both targeting ligands directed to such
transcytosis pathways as well as ligands mediating subsequent targeting and infection of
tumour cells present beyond the vascular wall[30].
3.7 Viral vector-associated multifunctional particles (MFPs) 
Nanotechnology has recently been incorporated into viral vector systems in the form of 
multifunctional particles (MFPs). Nanotechnology is defined as the development of devices 
of 100 nm or smaller, having unique properties due to their scale. The devices that are being 
developed generally incorporate inorganic or biological material. In this regard, the
coupling of inorganic nano-scale materials to targeted AV vectors has much potential for 
tumour targeting, imaging and amplified tumour killing capacities. For example, magnetic
nano-particles have recently received much attention due to their potential application in
clinical cancer treatment; targeted drug delivery and magnetic resonance imaging (MRI)
contrast agents[31]. However, despite the useful functionalities that might derive from metal
nanoparticle systems, the lack of targeting strategies has limited their application to
locoregional disease. Thus, tumour-selective delivery is the key to improve therapeutic 
applications of this technology.
AAV has been developed  with MFP, by virtue of genetic capsid modifications, to  
incorporate additional functionalities, such as modified fibres, combined with imaging 
motifs on the pIX protein, to simultaneously target tumour cells while monitoring viral 
replication and spread. Herpes simplex virus thymidine kinase (HSV TK) has been 
incorporated at pIX site of the AAV capsid. This enzyme is compatible with available PET 
imaging ligands such as 18F-penciclovir, providing an imaging system for viral replication 
that can directly be translated for clinical applications. Interestingly, HSV TK is an enzyme
that has utility in so-called suicide gene therapy, in which the expressed enzyme converts a 
substrate such as ganciclovir to its phosphorylated metabolite, which can then be further 
phosphorylated by cellular kinases to a toxic metabolite, causing cell death[32]. Also,
tumour cells expressing this gene product induce the death of adjacent cells via the so-called 
'bystander effect', thus representing an 'amplifying strategy' as mentioned above. 
3.8 Oncolytic virus
An oncolytic virus is a virus that has the ability to infect cancer cells and cause oncolysis.  It
is with obvious reasons that these types of viruses have received much attention in the field
of cancer therapy as they can result in direct destruction of the tumour cells.  Initial research 
into the anticancer potential of oncolytic viruses examined naturally occurring oncolytic 
viruses including adenovirus, poliovirus and Coxsackie virus[33-36]. However, these studies 
highlighted a number of limitations with naturally occurring oncolytic viruses including 
uncontrolled infection, incomplete oncolysis and the development of an immune
response[33, 35]. The stimulation of the immune system prevented the virus from 
destroying the cancer and therefore reduced the efficacy of the treatment.  Due to these
limitations many researchers discontinued their research into naturally occurring oncolytic 
viruses.
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304 Gene Therapy - Developments and Future Perspectives 
Recent advances in genetic modification techniques of oncolytic viruses have again awoken 
researchers’ interest into these agents for cancer therapy. There are now many different
oncolytic viruses currently being trailed as potential therapeutic agents (Table 2)(reviewed 
in [37]). The first to be produced for the clinic was ONYX-015 which has been shown to be a 
safe anticancer agent[38, 39].  
Name Oncolytic virus strain Type of tumour 
Head & neck
Ovarian 
ONYX-015 Adenovirus Primary & secondary liver 
tumours
Pancreatic 
CV706 Adenovirus Prostate
CV787 Adenovirus Prostate
G207 HSV Glioma 
NV1020 HSV 
Colorectal 
Liver metastases 
Vaccinia-GM-CSF Vaccinia Melanoma
PV701 NDV Advanced solid tumour 
1716 HSV 
Glioma
Melanoma 
Table 2. List of oncolytic viruses used in clinical trials (adapted from [37]). 
4. Limitation of viral vectors
Although both viral vectors and oncolytic viruses are widely used in cancer gene therapy 
research, these vectors suffer from several limitations. The first of these is the virus’s 
inability to specifically seek out and target the tumour.  The majority of therapies that utilize
these vectors currently require intratumoural injection to elicit an effect. Whilst this 
approach may be beneficial in some cases, its uses are limited as many tumours are 
inaccessible and may have already spread to other areas of the body at the time of diagnosis 
and treatment, making them difficult to locate and treat.  Another deficiency of viral vectors 
is their lack of capacity to efficiently penetrate and kill every cell within the tumour mass.
This results in non-tumour stromal cells being unaffected thus having the ability to regrow 
into another tumour. Finally, the tumours hypoxic microenvironment also reduces the 
effectiveness of the viral vector.  
Hypoxia is a prevalent feature found within most solid tumours. When a tumour grows to
and exceeds about 2mm in diameter, the local vasculatures of the surrounding normal 
tissues become inadequate to support the growing mass[40]. This results in a increase in 
angiogenesis within the tumour resulting in the tumour becoming more vascularised.
However, the normal efficient vascular architecture is disturbed and chaotic inside the 
growing tumour mass which leads to areas of tumour hypoxia, acidity, nutrient deficiency
and cell death. These hypoxic regions have the ability to reduce the effectiveness of viral
vectors thereby decreasing gene expression and proliferation leaving a proportion of the 
tumour mass unaffected, which may result in tumour regrowth.
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305Cancer Gene Therapy - Developments and Future Perspectives 
4.1 Oncolytic clostridia 
Solid tumours account for approximately 90% of all diagnosed cancer. Our current 
understanding of the unique microenvironment of solid tumours has highlighted the
deficiencies of both traditional therapies and new viral gene therapies and now requires a
rethink in the design of vectors. As mentioned, this hypoxic core provides a barrier for
current gene therapy vectors; however, it is also the perfect environment for anaerobic
bacteria. 
Class Species Features Advantages Disadvantages 
Class I:  B. longum  
Gram+ non­
motile  
Non-pathogenic 
present in common 
intestinalflora, 
No obvious oncolytic 
effect 
Bifido- 
bacteria 
B. adolescentis 
B. infantis 
obligate 
anaerobes 
Have been used in 
human for many 
years
 Probiotic bacteria 
Non-spore former  
More susceptible to
non-
Can be used for 
intravenous or oral 
administration
permissive
conditions 
Expression of
recombinant protein 
More difficult to store 
and handle 
Class II:
Facultative  
intracellular  
bacteria 
Salmonella
S. typhimurium 
S. choleraesuis  
Listeria
L.
monocytogenes  
E. coli
Gram_ 
facultative
anaerobes 
Agent for 
intestine 
infection 
Gram+, 
facultative
anaerobes 
Gram_, 
Attenuated vaccine 
strain has been 
proved safe
clinically in human, 
Biochemistrypathway 
s and 
genomes are well
characterized 
Auxotrophic isolates 
for 
solid tumours have 
intrinsic antitumour 
activity 
Grow under aerobic 
and anaerobic 
conditions, thus 
can target both large 
and 
small tumours, enter 
Intracellular bacteria,
thus may have 
difficulty to 
infect and lyse
quiescent  
cell
Have a tumour to 
normal tissue ratio of
1000:1, 
therefore a significant 
number of bacteria 
colonize normal 
organs 
Cell wall components 
are 
immunogenic
Virulence factors 
exist, especially LPS
in the 
bacterial cell wall,
thus 
safety is an issue 
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306 Gene Therapy - Developments and Future Perspectives 
Class Species Features 
facultative
Advantages 
professional antigen 
Disadvantages 
when large amount 
of bacteria
anaerobes 
presenting cells and
induce strong innate 
immune response 
Have the potential as
a vaccine vector for 
are delivered 
tumour 
therapy 
Biology is well
studied and known  
Class III:  
Strictly 
Clostridium 
Proteolytic 
Gram+, 
strictly
anaerobes 
Spore former 
Spores are stable, easy 
to 
Some strains are 
pathogenic 
Anaerobic 
bacteria 
C. sporogenes  
Saccharolytic
C. novyi 
normal 
habitat in the
soil,
aquatic 
sediments,
and 
intestinal
tract of both 
produce and 
economic to use 
Clostridialspores can 
be delivered non­
invasively
and systemically, i.e. 
intravenous injection
Some strains are 
difficult to
manipulate 
genetically
Only colonize in
large tumours with 
area of
hypoxia/necrosis 
C. butyricum 
C. 
acetobutylicum
animals and 
humans
Have shown extensive 
oncolytic ability
Spores are non-
immunogenic and can 
be 
Oncolysis interrupted 
at the rim causing 
incomplete
tumour lysis 
C. oncolyticum 
C. beijerinckii 
 repeatedly delivered
Oncolysis occurs 
irrespective of tumour 
cells’
heterogeneity or 
growth
status 
Table 3. Types of aerobic and facultative anaerobes used in cancer gene therapy (adapted 
from [41]).
Both facultative and obligate anaerobic bacteria have several advantages over traditional 
viral vector systems as they have been shown to selectively target, colonise and regerminate
into vegetative cells in the hypoxic microenvironment of solid tumours when delivered 
systemically (Table 2)[41].   One such bacterium, the strictly anaerobic Clostridia, have also
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307Cancer Gene Therapy - Developments and Future Perspectives 
been shown to cause tumour lysis and destruction even without any genetic modification.
A number of non-pathogenic strains of Clostridia have also shown plausible safety when 
used in humans.  However, these vectors also have limitations.  As these bacterium require 
an anaerobic environment to survive, oncolysis is almost always stalled at the proliferative 
outer rim of the tumour mass.  More recently, combinational approaches have to be 
implemented to deal with these limitations and a number of trials have commenced to test
these protocols. 
The intrinsic property of Clostridia to specifically target and colonise only within the hypoxic 
core of the tumour enables them to serve as perfect vectors for the delivery of genes for
cancer therapy. Already, clostridial spores have been genetically manipulated to deliver
genes for cancerstatic factors, prodrug converting enzymes, or cytokines with the aim of
improving their innate oncolytic activity. Furthermore, when used in combination with
conventional chemotherapy or radiation therapies these vectors often perform better then 
Clostridia alone.  Another advantage of clostridial spores is their seemingly unlimited
capacity to carry exogenous genes. This remarkable characteristic will allow for the
development of novel ways to equip Clostridia with gene combinations that may have the
ability to break immune suppression, overcome the limitation of tumour lysis in the outer 
rim or cause a strong anti-tumour response with the ability to eliminate tumour metastases, 
the ultimate cause of cancer death. 
It is obvious that a major step towards the development of an effective cancer therapy will
be to construct a vector that targets the tumour alone, and is capable of spreading to and
throughout the tumour found in tissues. Clostridial spores fit into this equation very well.
Clostridia are strictly anaerobic. They are gram-positive, rod-shaped, and form spores under 
unfavourable conditions. There are about 80 species and several of these have been tested in 
solid tumours. All known species require anaerobic conditions to grow but do vary in their 
oxygen tolerance and their biochemical profile. Clostridial spores have been administered
intravenously and showed a distinct advantage for use in cancer therapy as they are easy to
produce and store. Germination of spores will only occur when they encounter the requisite 
anaerobic conditions. Spontaneous colonization of tumours in cancer patients and the
apparent selectivity of Clostridia for tumours were noticed more than 50 years ago. The first 
experiment in 1947 showed that direct injection of spores of C. histolyticum into mouse
sarcoma caused oncolysis (liquefaction) and tumour regression[42]. Later experiments 
proved this selectivity by injecting mice i.v. with spores of C. tetani, the causative agent of 
tetanus. Injected non-tumour bearing animals remained healthy. However, tumour bearing
mice died within 48 h because of C. tetani colonisation and tetanus production. This 
provided evidence that the C. tetani were able to germinate/replicate selectively in the
anaerobic environment found within tumours, and released their toxins systemically[6]. 
Obviously, it would not be appropriate to use pathogenic strains of Clostridia for clinical
therapy in humans. A non-pathogenic strain of C. butyricum M-55 has been isolated[43]. M­
55 was later reclassified as C. oncolyticum and taxonomic studies have now clearly 
established that it is a C. sporogenes strain (ATCC13732). This is a proteolytic species causing 
liquefaction of colonised tumours. This was later verified by testing more isolates. 
Saccharolytic clostridia, such as C. beijerinckii NCIMB8052 spores administered 
intravenously to EMT6 tumour-bearing mice germinated in the necrotic tumour regions 
while the oxygenated tumour areas remained free of spores[44]. Equally, intravenous 
injection of rhabdomyosarcoma-bearing rats with at least 107 spores of C. beijerinckii 
ATCC17778, C. acetobutylicum DSM792 (= ATCC824) or C. acetobutylicum NI-4082
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308 Gene Therapy - Developments and Future Perspectives 
(reclassified as C. saccharoperbutylacetonicum) showed tumour colonisation without complete
tumour lysis[45]. 
C. sporogenes was the first Clostridium to be gene modified and this was performed with the
E. coli Colicin E3 gene. Colicin E3 encodes a bacteriocin shown to have canceriostatic 
properties[46]. However, the overall anti-tumour efficacy of this bacteriocin was limited.
This may have resulted from poor gene modification methodologies which were improved 
with the application of electroporation. In 2002 Prof. Brown's group introduced E. coli 
cytosine deaminase (CD) into C. sporogenes NCIMB10696 by electroporation[47]. Intravenous 
injection of the recombinant spores followed by the systemic administration of the prodrug 
5-FC inhibited tumour growth which was more pronounced than the use of prodrug alone. 
Unfortunately, for reasons unknown this inhibition in tumour growth did not persist.
However, it was clear that C. sporogenes has a great capacity to colonise the tumour. At least 
10e8 CFU/g of tumour was obtained following the intravenous injection of the spores. 
Saccharolytic Clostridia strains including C. beijerinckii ATCC17778, C. acetobutylicum
DSM792 (ATCC824) or C. acetobutylicum NI4082 (reclassified as C.
saccharoperbutylacetonicum) and C. butyricum are non-pathogenic and their development has
been industry funded. Therapeutic genes, encoding the cytokine tumour necrosis factor 
alpha (TNF-α), CD or nitroreductase (NTR) have been introduced into these strains[48, 49].
Following transformation of C. acetobutylicum using strain-specific electroporation protocols, 
CD expression was monitored in lysates and supernatants of early logarithmic growth 
phase cultures of recombinant C. acetobutylicum (pKNT19closcodA)[50]. A considerable 
amount of heterologous protein was expressed and efficiently secreted. Also, C. 
acetobutylicum strains NI4082 and DSM792 engineered to produce cytosine deaminase were
able to express and secrete this enzyme at the tumour site[48, 49]. Functional CD enzyme
was detected in the tumour of rhabdomyosarcoma-bearing WAG/Rij rats that were injected 
with the recombinant C. acetobutylicum, but not in control animals. Animals, concomitantly 
treated with antivascular chemical agent, CombreAp, showed higher incidence of CD-
positive tumours (100 versus 58%). Moreover, the level of active CD in these tumour 
specimens was considerably higher (mean conversion efficiency of 5-FC to 5-FU ~11%) as
compared to tumours not treated with the vascular targeting drug (mean conversion
efficiency of 5-FC to 5-FU ~11%) when compared to untreated tumours (mean conversion 
efficiency of 5-FC to 5-FU ~3%)[49]. However, when these recombinant strains were used in 
solid tumour models in vivo, there was a consistent lack of significant tumour regression 
observed. Factors that may have contributed to this lack of efficacy include a low level of 
bacterial colonisation of the tumour or insufficient recombinant gene expression and
secretion at the tumour site[51]. Recent studies have reported the development of vectors
utilising super tumour coloniser Clostridial strains C. sporogenes or C. novyi-NT. Recombinant 
C. sporogenes and C. novyi-NT overexpressing NTR showed significant in vivo anti-tumour 
effects[52] when used with prodrug demonstrating the clinical potential of these vectors.
5. Advantages of clostridial spores for cancer gene therapy
At present, there are various gene therapy vector systems under development against 
cancer. However, due to the complexity of the solid tumours involving angiogenesis,
hypoxia, stromal cell, tumour cell heterogeneity and the emergence of de-differentiated 
stem cells, none of the existing vectors are holding any real promises. The clostridial spore-
based vector system is not infectious, and has gained renewed interest, because of the 
following true advantages.  
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309Cancer Gene Therapy - Developments and Future Perspectives 
5.1 Preferentially growing within the unique tumour microenvironment 
The biological properties of virus-based vectors, in particular the ability to enter and
replicate (in the case of replication-competent viral vectors) within a tumour cell and then 
spread from cell to cell are highly relevant for effective cancer therapy. However, recent 
understanding of tumour pathology has revealed that several features of the tumour 
environment may not be conducive for viral replication[40, 53]. Hypoxia is an important
feature of solid tumours and the ability of viruses to enter and replicate in hypoxic cells may 
be a critical determinant for the success or failure of viral vector-mediated cancer gene
therapy. Turning off protein translation is a central process in the cellular adaptation to
many types of stress, including viral infection and hypoxia. The hypoxic cells, the apoptotic
cells, the quiescent cells are all refractory to viral entry and replication[54]. This is a major
problem for virus-based vectors because if the vector can't reach a tumour cell, it can't act or 
deliver a therapeutic gene. On the contrary, clostridial spores are able to home in on these 
niche environments because of their own unique metabolic need, which enable them to
utilise the tumour micro milieu and respective tissues for their own proliferation. Both wild-
type and genetically modified Clostridia have been demonstrated to specifically colonise
and destroy solid tumours. "Trojan horse" vectors have further created improved features 
that enable them to kill tumour cells through multimodality mechanisms. 
5.2 Easy production
All of the viral vector systems need sophisticated cell culture systems, expensive culture 
media, rounds of filtrations and purifications and dedicated centrifugation and storages. On 
the contrary, clostridial spores can be easily and inexpensively produced from anaerobic 
bacterial culture. There are only a few steps involved and the spores, once produced can be 
stored at room temperature for at least 3–6 months. 
5.3 Easy administration
While most viral vectors have to be intratumourally injected, intravenous injection of 
resuspended clostridial spores are possible and sufficient as they will be leaked out of the 
incomplete vessels in the solid tumour, thus specifically targeting to and colonising the 
hypoxic regions of the tumours.
5.4 Safety
Safety is always a concern when live vector systems are used for human gene therapy. Some 
of the hurdles of using viral vectors include: (1) whether the vector is sufficiently targeted to
tumour alone; (2) whether the vector expresses low levels of viral genes that may lead to
increased toxicity and immunogenicity[55]; (3) possible immunogenicity of the transgene
that may be reduced with a reduction in the duration of gene expression[56]; and (4) 
whether viral particles are sequested within the target cells or secreted into body fluid such 
as urine and subsequently spread into environment. We postulate that the use of clostridial 
spore based vectors may be a safer option to using viral vectors. Clostridia are strictly 
anaerobic, are tumour targeted and would be unable to live in non-hypoxic environments. A 
recent experiment with C. novyi-NT has demonstrated that the strain was unable to colonise 
artificially created infarcted heart where the level of hypoxia was inadequate to support the 
replication of the Clostridia[7]. Early trials of non-pathogenic Clostridia strains in patients
have demonstrated safety. In the unlikely event of an adverse effect, clostridia can be 
eliminated from the blood stream with the use of readily available antibiotics such as 
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metronidazole which showed total spore clearance from the blood stream after 9 days of 
treatment[4]. 
6. Indiscriminant destruction of all cell types within the tumour
Solid tumours comprise not only malignant cells, but also extracellular matrix and many 
other non-malignant cell types, including stromal cells such as fibroblasts, endothelial cells
and inflammatory cells. The mechanisms of clostridial vector-mediated tumour killing 
consist of several aspects: one is from its transgene that encodes prodrug converting 
enzymes for suicide-gene therapy or cytokines for immuno-gene therapy. These are
essentially the same as the viral vectors. However, there is another side of the tumour killing
effect that is resulting from the consequences of an innate antitumour effect of the clostridial 
strain due to production of hydrolytic enzymes including proteases, lipases, and nuclease.
Furthermore, there is also a nutrients competition between the clostridia and cells
surrounding them (including tumour cells, stromal cells and stem cells), where the clostridia 
multiplied much faster than the mammalian cells. The cumulative multiplications and the 
combined events of energy and substance metabolism effectively depleted the limited
nutrient source and deprive the tumour cells, causing starvation and death. More recently, 
there were observations that indicate the germination of the clostridial spores, the
transformation from spores to vegetative rods, and the continue multiplications of the
vegetative rods inside the tumour activated the immune system, assisting the antitumour 
effects[57]. These tumour killing mechanisms destroy not only tumour cells, but also any 
other cells in their vicinity. These are characteristics that viral vectors are not so well
equipped, nor any existing convectional cancer therapies. 
6.1 Extracellular agent 
While viral vectors need access to viable target cells and their cellular machinery to achieve 
transgene delivery and expression, this goal is often difficult to fulfil as some tumour cells
are not viable at the time of gene delivery. Furthermore, none of the existing vector systems
efficiently transfer genes to every tumour cell which subsequently allows for tumour
regrowth. On the other hand clostridial spore replication is not tumour cell dependent and
occurs via rod multiplication extra-cellularlly. Furthermore, the tumour killing mechanism
of clostridial spores may operate independently of the requirement for gene transfer. 
Without the requirement for gene integration into the host cell genome removes the
possibility of insertional mutagenesis when using Clostridia. Therefore, Clostridia may 
show tumour killing irrespective of the tumour cell heterogeneity found within the tumour
environment. 
6.2 No restrictions on accommodating therapeutic genes
One of the primary limitations of most viral vectors has been the small size of the virion, 
which only permits the packaging of very limited sizes (usually a few kilobases) of 
exogenous DNA that includes the promoter, the polyadenylation signal and any other 
enhancer elements that might be desired. However, for clostridia size limitations are far less 
restricted, not only because the plasmids used can harbour much larger DNA fragments, but 
in case the foreign gene is integrated in the host chromosome there is in fact unlimited 
capacity for insertion of therapeutic genes, forecasting the promising future for the
development of ever powerful vectors. 
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7. Other developments for cancer gene therapy
Another potential direction for cancer gene therapy has come from the discovery of small 
non-coding RNAs that can significantly interfere with gene expression levels at the post-
transcriptional level.  RNA interference (RNAi) is an evolutionary conserved mechanism for 
specific gene silencing that can result in the degradation or inhibition of homologous
mRNA. The most widely studied types of RNAi include both micro-RNA (miRNA) and
short interfering RNA (siRNA). 
Post-transcriptional gene silencing by RNAi represents an essential part of endogenous gene
regulation, with much evidence to suggest that RNAi regulates more than one third of all 
cellular mRNAs, and that each RNAi can control hundreds of gene targets in both normal 
and diseased conditions.  More recently mutations or aberrant expression patterns in RNAi 
have been shown to correlate with various diseases, including cancer, and indicate that
some RNAi may have a tumour suppressor function or operate as oncogenes.  It is now  
believed that RNAi may prove to be a beneficial factor in the treatment of cancer by either 
altering the endogenous levels of these RNAi or by the introduction of new RNAi to alter 
the expression of cancer causing genes.  
RNAi therapy has already been trialled in a number of different models, however, several 
critical limitations must first be overcome. These limitations include non-specific effects in 
non-tumour tissue, potential toxicity due to interactions with endogenous RNAi, half-life of
silencing, and inability to specifically target only the tumour mass. One possible approach, 
to overcome many of these limitations, is to use RNAi in combination with Clostridia as a 
gene delivery system to the hypoxic core of the tumour.  
8. Conclusion 
The unique pathophysiology of solid tumours presents a huge problem for the conventional
therapies. Thus, the outcomes of current therapies are so far disappointing. Several new 
approaches aiming at developing effective treatments are on the horizon. These include a 
variety of virus-based therapy systems[2, 58, 59]. Amongst all these, replication-competent 
viral vector-mediated cancer therapy is most promising[60, 61]. However, even this system
suffers from several deficiencies: First, the vectors currently have to be injected  
intratumourally to elicit an effect. This is far from ideal as many tumours are inaccessible and
spread to other areas of the body making them difficult to detect and treat. Second, because of 
the heterogeneity within a tumour, the vector does not efficiently enter and spread to sufficient
numbers of tumour cells. Third, hypoxia, a prevalent characteristic feature of most solid 
tumours, reduces the ability of the viral vector to function and decrease viral gene expression
and production. Consequently, a proportion of the tumour mass is left unaffected and capable 
of re-growing. Fourth, pre-existing immunity pose a problem for the efficacy of viral vectors.
Therefore, there have rarely been any cures with the use of the system.  
The strictly anaerobic clostridia, on the other hand, have been shown to selectively colonise in
solid tumours when delivered systemically and has resulted in high percentage of "cures" of
experimental tumours. A phase I clinical trial combining spores of a non toxic strain (C. novyi-
NT) with an antimicrotubuli agent has been initiated[62]. Genetic manipulation of clostridia to 
make them into "Trojan horse" vectors will provide further tumour killing mechanisms and
amplifying antitumour effects. Clearly, it is just a matter of time that a "Trojan horse" type of 
clostridium will become a clinical reality, especially if we can further improve upon the system 
by providing additional features, ideally including (i) targeting tumours only and not 
anywhere else, (ii) able to effective kill primary tumours as well as metastases. Current
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technologies are in place to achieve these goals. Newer and effective therapies for solid
tumours based on the "Trojan horse" will be a reality in a very near future. 
9. References
[1] Toloza, E.M., Gene therapy for lung cancer. Thoracic Surgery Clinics, 2006. 16(4): p. 397-419, vii. 
[2] Kasono, K., et al., Selective gene delivery to head and neck cancer cells via an integrin targeted 
adenoviral vector. Clinical Cancer Research, 1999. 5(9): p. 2571-9. 
[3] Heppner, F. and J.R. Mose,  The liquefaction (oncolysis) of malignant gliomas by a non 
pathogenic Clostridium. Acta Neurochirurgica, 1978. 42(1-2): p. 123-5. 
[4] Nuyts, S., et al., Clostridium spores for tumor-specific drug delivery. Anti-Cancer Drugs, 2002. 
13(2): p. 115-25. 
[5] Wei, M.Q., et al.,  Clostridial spores as live 'Trojan horse' vectors for cancer gene therapy:
comparison with viral delivery systems. Genetic Vaccines & Therapy, 2008. 6: p. 8. 
[6] Malmgren, R.A. and C.C. Flanigan, Localization of the vegetative form of Clostridium tetani in 
mouse tumors following intravenous spore administration. Cancer Res. , 1955. 15: p. 473–8.
[7] Diaz, L.A., Jr., et al.,  Pharmacologic and toxicologic evaluation of C. novyi-NT spores.
Toxicological Sciences, 2005. 88(2): p. 562-75. 
[8] Raty, J.K., et al., Gene therapy: the first approved gene-based medicines, molecular mechanisms 
and clinical indications. Current Molecular Pharmacology, 2008. 1(1): p. 13-23. 
[9] Colombo, F., et al.,  Combined HSV-TK/IL-2 gene therapy in patients with recurrent
glioblastoma multiforme: biological and clinical results. Cancer Gene Therapy, 2005. 
12(10): p. 835-48. 
[10] Seth, P., Vector-mediated cancer gene therapy: an overview. Cancer Biology & Therapy, 2005. 
4(5): p. 512-7.
[11] Rein, D.T., M. Breidenbach, and D.T. Curiel, Current developments in adenovirus-based
cancer gene therapy. Future Oncology, 2006. 2(1): p. 137-43. 
[12] Peng, Z., Current status of gendicine in China: recombinant human Ad-p53 agent for treatment
of cancers. Human Gene Therapy, 2005. 16(9): p. 1016-27. 
[13] Wang, X.Y., et al., Preclinical evaluation of a prostate-targeted gene-directed enzyme prodrug 
therapy delivered by ovine atadenovirus. Gene Therapy, 2004. 11(21): p. 1559-67. 
[14] Matthews, Q.L., et al., Genetic incorporation of a herpes simplex virus type 1 thymidine kinase
and firefly luciferase fusion into the adenovirus protein IX for functional display on the 
virion.[Erratum appears in Mol Imaging. 2007 Jan-Feb;6(1):72]. Molecular Imaging:
Official Journal of the Society for Molecular Imaging, 2006. 5(4): p. 510-9.
[15] Flotte, T.R., Gene therapy progress and prospects: recombinant adeno-associated virus (rAAV)
vectors. Gene Therapy, 2004. 11(10): p. 805-10. 
[16] Urabe, M., et al., Scalable generation of high-titer recombinant adeno-associated virus type 5 in
insect cells. Journal of Virology, 2006. 80(4): p. 1874-85. 
[17] Young, L.S., et al., Viral gene therapy strategies: from basic science to clinical application.
Journal of Pathology, 2006. 208(2): p. 299-318. 
[18] Ram, Z., et al., Therapy of malignant brain tumors by intratumoral implantation of retroviral 
vector-producing cells. Nature Medicine, 1997. 3(12): p. 1354-61. 
[19] Tai, C.-K., et al., Single-shot, multicycle suicide gene therapy by replication-competent retrovirus 
vectors achieves long-term survival benefit in experimental glioma. Molecular Therapy: the 
Journal of the American Society of Gene Therapy, 2005. 12(5): p. 842-51.
[20] Buchholz, C.J. and K. Cichutek, Is it going to be SIN?: a European Society of Gene Therapy 
commentary. Phasing-out the clinical use of non self-inactivating murine leukemia virus 
vectors: initiative on hold. Journal of Gene Medicine, 2006. 8(10): p. 1274-6. 
www.intechopen.com
  
 
 
 
 
 
 
 
 
  
 
 
  
  
  
 
 
 
 
 
 
    
  
 
 
  
 
 
313Cancer Gene Therapy - Developments and Future Perspectives 
[21] Naldini, L., et al., In vivo gene delivery and stable transduction of nondividing cells by a 
lentiviral vector. Science, 1996. 272(5259): p. 263-7. 
[22] Levine, B.L., et al., Gene transfer in humans using a conditionally replicating lentiviral vector.
Proceedings of the National Academy of Sciences of the United States of America, 
2006. 103(46): p. 17372-7.
[23] Metharom, P., et al., Novel bovine lentiviral vectors based on Jembrana disease virus. Journal 
of Gene Medicine, 2000. 2(3): p. 176-85. 
[24] Metharom, P., et al., The development of bovine lentiviral vectors based on the Jembana disease
virus, an infectious agent of cattle. Vet Microbiol, 2000. 80: p. 9-22. 
[25] Harland, J., et al., The herpes simplex virus (HSV) protein ICP34.5 is a virion component that
forms a DNA-binding complex with proliferating cell nuclear antigen and HSV replication 
proteins. Journal of Neurovirology, 2003. 9(4): p. 477-88. 
[26] Derubertis, B.G., et al., Cytokine-secreting herpes viral mutants effectively treat tumor in a
murine metastatic colorectal liver model by oncolytic and T-cell-dependent mechanisms.
Cancer Gene Therapy, 2007. 14(6): p. 590-7.
[27] Lee, J.-S., et al., Growth inhibitory effect of triple anti-tumor gene transfer using Semliki Forest virus
vector in glioblastoma cells. International Journal of Oncology, 2006. 28(3): p. 649-54. 
[28] Izsvak, Z., Z. Ivics, and R.H. Plasterk, Sleeping Beauty, a wide host-range transposon vector for
genetic transformation in vertebrates. Journal of Molecular Biology, 2000. 302(1): p. 93-102. 
[29] Zhu, Z.B., et al., Transport across a polarized monolayer of Caco-2 cells by transferrin receptor-
mediated adenovirus transcytosis. Virology, 2004. 325(1): p. 116-28. 
[30] McIntosh, D.P., et al., Targeting endothelium and its dynamic caveolae for tissue-specific
transcytosis in vivo: a pathway to overcome cell barriers to drug and gene delivery.
Proceedings of the National Academy of Sciences of the United States of America, 
2002. 99(4): p. 1996-2001. 
[31] Pankhurst, Q.A. and et al., Applications of magnetic nanoparticles in biomedicine. Journal of
Physics D: Applied Physics, 2003. 36(13): p. R167. 
[32] Li, J., et al., Genetic incorporation of HSV-1 thymidine kinase into the adenovirus protein IX for 
functional display on the virion. Virology, 2005. 338(2): p. 247-58. 
[33] Kuruppu, D. and K.K. Tanabe, Viral oncolysis by herpes simplex virus and other viruses.
Cancer Biology & Therapy, 2005. 4(5): p. 524-31. 
[34] Voroshilova, M.K., Potential use of nonpathogenic enteroviruses for control of human diseases.
Progress in medical virology 1989. 36 p. 191–202. 
[35] Pond, A.R. and E.E. Manuelidis, Oncolytic effect of poliomyelitis virus on human epidermoid 
carcinoma (HeLa tumor) heterologously transplanted to guinea pigs. The American 
Journal of Pathology, 1964. 45 p. 233–49. 
[36] Kunin, C.M., Cellular susceptibility to enteroviruses. Bacteriological reviews 1964. 28 p. 382-90.
[37] Meerani, S. and Y. Yao, Oncolytic viruses in cnacer therapy. European Journal of Scientific
Research, 2010. 40(1): p. 156 - 171. 
[38] Lamont, J.P., et al., A prospective phase II trial of ONYX-015 adenovirus and chemotherapy in 
recurrent squamous cell carcinoma of the head and neck (the Baylor experience). Annals of 
Surgical Oncology, 2000. 7(8): p. 588-92. 
[39] Nemunaitis, J., et al., Selective replication and oncolysis in p53 mutant tumors with ONYX-
015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck 
cancer: a phase II trial. Cancer Research, 2000. 60(22): p. 6359-66. 
[40] Folkman, J., What is the evidence that tumors are angiogenesis dependent? Journal of the 
National Cancer Institute, 1990. 82(1): p. 4-6.
[41] Wei, M.Q., et al., Facultative or obligate anaerobic bacteria have the potential for multimodality 
therapy of solid tumours. European Journal of Cancer, 2007. 43(3): p. 490-6.
www.intechopen.com
  
 
 
 
 
 
 
  
 
 
  
 
 
 
 
  
 
 
 
314 Gene Therapy - Developments and Future Perspectives 
[42] Parker, R.C., et al., Effect of hispolyticus infection and toxin on transplantable mouse tumours.
Proc Soc Exp Biol Med. , 1947. 66: p. 461–465. 
[43] Möse, J.R. and G.Z. Möse, Onkolyseversuche mit apathogen, anaerogen sporenbildern am
Erhlich-Tumor der maus Z Krebsforsch, 1959. 63: p. 63–74. 
[44] Lemmon, M.J., et al., Anaerobic bacteria as a gene delivery system that is controlled by the
tumor microenvironment. Gene Therapy, 1997. 4(8): p. 791-6.
[45] Lambin, P., et al., Colonisation of Clostridium in the body is restricted to hypoxic and necrotic 
areas of tumours. Anaerobe, 1998. 4(4): p. 183-8.
[46] Schlechte, H. and B. Elbe, Recombinant plasmid DNA variation of Clostridium oncolyticum--
model experiments of cancerostatic gene transfer. Zentralblatt fur Bakteriologie, 
Mikrobiologie, und Hygiene - Series A, Medical Microbiology, Infectious Diseases, 
Virology, Parasitology, 1988. 268(3): p. 347-56. 
[47] Liu, S.C., et al., Anticancer efficacy of systemically delivered anaerobic bacteria as gene therapy 
vectors targeting tumor hypoxia/necrosis. Gene Therapy, 2002. 9(4): p. 291-6.
[48] Theys, J., et al., Clostridium as a tumor-specific delivery system of therapeutic proteins. Cancer
Detection & Prevention, 2001. 25(6): p. 548-57. 
[49] Van Mellaert, L., S. Barbe, and J. Anne, Clostridium spores as anti-tumour agents. Trends in 
Microbiology, 2006. 14(4): p. 190-6. 
[50] Theys, J., et al.,  Specific targeting of cytosine deaminase to solid tumors by engineered 
Clostridium acetobutylicum. Cancer Gene Therapy, 2001. 8(4): p. 294-7. 
[51] Wei, M.Q., et al., Bacterial targeted tumour therapy-dawn of a new era. Cancer Letters, 2008.
259(1): p. 16-27. 
[52] Theys, J., et al., Repeated cycles of Clostridium-directed enzyme prodrug therapy result in 
sustained antitumour effects in vivo. British Journal of Cancer, 2006. 95(9): p. 1212-9. 
[53] Vaupel, P. and A. Mayer, Hypoxia in cancer: significance and impact on clinical outcome.
Cancer & Metastasis Reviews, 2007. 26(2): p. 225-39. 
[54] Hay, J.G., The potential impact of hypoxia on the success of oncolytic virotherapy. Current
Opinion in Molecular Therapeutics, 2005. 7(4): p. 353-8. 
[55] Raper, S.E., et al.,  Fatal systemic inflammatory response syndrome in a ornithine
transcarbamylase deficient patient following adenoviral gene transfer. Molecular Genetics 
& Metabolism, 2003. 80(1-2): p. 148-58. 
[56] Yang, Y., et al., Cellular and humoral immune responses to viral antigens create barriers to 
lung-directed gene therapy with recombinant adenoviruses. Journal of Virology, 1995.
69(4): p. 2004-15. 
[57] Janssen, H.L., et al., Hypoxia in head and neck cancer: how much, how important? Head & 
Neck, 2005. 27(7): p. 622-38. 
[58] Agrawal, N., et al.,  Bacteriolytic therapy can generate a potent immune response against 
experimental tumors. Proceedings of the National Academy of Sciences of the United 
States of America, 2004. 101(42): p. 15172-7. 
[59] Huang, Q., et al., A novel conditionally replicative adenovirus vector targeting telomerase-
positive tumor cells. Clinical Cancer Research, 2004. 10(4): p. 1439-45. 
[60] Papanastassiou, V., et al.,  The potential for efficacy of the modified (ICP 34.5(-)) herpes 
simplex virus HSV1716 following intratumoural injection into human malignant glioma: a 
proof of principle study. Gene Therapy, 2002. 9(6): p. 398-406. 
[61] Pipiya, T., et al., Hypoxia reduces adenoviral replication in cancer cells by downregulation of
viral protein expression. Gene Therapy, 2005. 12(11): p. 911-7.
[62] http://www.clinicaltrials.gov/ct. 
www.intechopen.com
Gene Therapy - Developments and Future Perspectives
Edited by Prof. Chunsheng Kang
ISBN 978-953-307-617-1
Hard cover, 356 pages
Publisher InTech
Published online 22, June, 2011
Published in print edition June, 2011
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
The aim of this book is to cover key aspects of existing problems in the field of development and future
perspectives in gene therapy. Contributions consist of basic and translational research, as well as clinical
experiences, and they outline functional mechanisms, predictive approaches, patient-related studies and
upcoming challenges in this stimulating but also controversial field of gene therapy research. This source will
make our doctors become comfortable with the common problems of gene therapy and inspire others to delve
a bit more deeply into a topic of interest.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
David Good, Wei Duan, Jozef Anné and Ming Wei (2011). Cancer Gene Therapy- Developments and Future
Perspectives, Gene Therapy - Developments and Future Perspectives, Prof. Chunsheng Kang (Ed.), ISBN:
978-953-307-617-1, InTech, Available from: http://www.intechopen.com/books/gene-therapy-developments-
and-future-perspectives/cancer-gene-therapy-developments-and-future-perspectives
© 2011 The Author(s). Licensee IntechOpen. This chapter is distributed
under the terms of the Creative Commons Attribution-NonCommercial-
ShareAlike-3.0 License, which permits use, distribution and reproduction for
non-commercial purposes, provided the original is properly cited and
derivative works building on this content are distributed under the same
license.
